Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- Check2 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations related to breast cancer treatment, while also removing previous references to certain locations and medical terms.SummaryDifference2%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check23 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check30 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
- Check37 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.1%
- Check44 days agoChange DetectedThe service alert has been updated to reflect a planned maintenance period starting on July 25th, with services expected to be unavailable for over 24 hours, compared to the previous alert which indicated maintenance starting on July 26th for 12+ hours.SummaryDifference0.3%
Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.